Simultaneous Auger-e- and β--Particle therapy of metastasized NET using 161Tb-DOTATOC
Researcher: Roger Schibli, Ph.D. Location: Paul Scherrer Institut, Zurich, Switzerland State: Outside of the U.S. Year: 2018 Status: Active Award: Petersen Investigator Award
Leave it blank
This two-year Petersen Project will explore the safety of a novel radionuclide for more effective treatment of NETs. Despite the effectiveness of PRRT to prolong survival, many patients will be diagnosed with metastases a few years later. Schibli and colleagues will develop a new therapy based on terbium radionuclides (161Tb), which have distinct radioactive properties, compared to Lu 177. The researchers will evaluate the ability of 161Tb-DOTATOC to kill single cancer cells and tiny metastases in a pre-clinical setting before they proceed with the first-in-man study. They theorize that this type of therapy will result in a paradigm shift in the treatment of NETs.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116